Murphy Pohlad Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.26M Sell
52,377
-5,560
-10% -$145K 0.44% 69
2026
Q1
$1.63M Sell
57,937
-4,858
-8% -$129K 0.58% 56
2025
Q4
$1.56M Sell
62,795
-19,641
-24% -$495K 0.6% 57
2025
Q3
$2.1M Sell
82,436
-34,459
-29% -$851K 0.82% 45
2025
Q2
$2.83M Sell
116,895
-7,070
-6% -$165K 1.2% 36
2025
Q1
$3.14M Buy
123,965
+8,740
+8% +$229K 1.33% 30
2024
Q4
$3.06M Sell
115,225
-31,044
-21% -$842K 1.32% 34
2024
Q3
$4.23M Buy
146,269
+12,645
+9% +$369K 1.76% 15
2024
Q2
$3.74M Buy
133,624
+6,000
+5% +$165K 1.61% 21
2024
Q1
$3.54M Sell
127,624
-1,205
-0.9% -$33.4K 1.39% 28
2023
Q4
$3.71M Buy
128,829
+1,850
+1% +$55.9K 1.53% 26
2023
Q3
$4.21M Buy
126,979
+10,415
+9% +$368K 1.85% 19
2023
Q2
$4.28M Buy
116,564
+5,450
+5% +$212K 1.84% 18
2023
Q1
$4.53M Buy
111,114
+265
+0.2% +$11.4K 1.88% 19
2022
Q4
$5.68M Buy
110,849
+1,042
+0.9% +$50K 2.32% 9
2022
Q3
$4.8M Buy
109,807
+2,098
+2% +$102K 2.22% 12
2022
Q2
$5.65M Buy
107,709
+1,580
+1% +$80.5K 2.48% 7
2022
Q1
$5.49M Buy
106,129
+2,950
+3% +$153K 2.21% 13
2021
Q4
$6.09M Sell
103,179
-100
-0.1% -$4.96K 2.4% 7
2021
Q3
$4.44M Buy
103,279
+3,200
+3% +$142K 1.81% 17
2021
Q2
$3.92M Buy
100,079
+3,647
+4% +$142K 1.59% 22
2021
Q1
$3.49M Buy
96,432
+3,840
+4% +$136K 1.52% 25
2020
Q4
$3.41M Buy
92,592
+26,019
+39% +$954K 1.69% 19
2020
Q3
$2.32M Buy
66,573
+7,273
+12% +$255K 1.23% 32
2020
Q2
$1.84M Buy
59,300
+5,908
+11% +$201K 1.03% 43
2020
Q1
$1.65M Buy
53,392
+3,414
+7% +$116K 1.13% 40
2019
Q4
$1.86M Buy
49,978
+2,130
+4% +$75.9K 1.02% 41
2019
Q3
$1.63M Buy
47,848
+780
+2% +$28.4K 1% 43
2019
Q2
$1.93M Sell
47,068
-949
-2% -$37.7K 1.16% 36
2019
Q1
$1.93M Sell
48,017
-5,402
-10% -$216K 1.17% 41
2018
Q4
$2.21M Sell
53,419
-2,071
-4% -$86K 1.54% 21
2018
Q3
$2.32M Sell
55,490
-11,894
-18% -$458K 1.43% 30
2018
Q2
$2.32M Sell
67,384
-3,284
-5% -$112K 1.55% 26
2018
Q1
$2.38M Sell
70,668
-1,966
-3% -$67.6K 1.64% 23
2017
Q4
$2.5M Sell
72,634
-2,656
-4% -$90.6K 1.65% 20
2017
Q3
$2.55M Buy
75,290
+1,981
+3% +$63.7K 1.77% 21
2017
Q2
$2.34M Sell
73,309
-5,469
-7% -$172K 1.72% 20
2017
Q1
$2.56M Sell
78,778
-2,086
-3% -$65.8K 1.89% 18
2016
Q4
$2.49M Buy
80,864
+16,037
+25% +$490K 1.8% 20
2016
Q3
$2.08M Buy
64,827
+2,492
+4% +$83.3K 1.55% 27
2016
Q2
$2.08M Hold
62,335
1.55% 23
2016
Q1
$1.75M Buy
62,335
+7,073
+13% +$202K 1.32% 30
2015
Q4
$1.69M Hold
55,262
1.34% 31
2015
Q3
$1.65M Hold
55,262
1.34% 35
2015
Q2
$1.76M Hold
55,262
1.32% 35
2015
Q1
$1.82M Sell
55,262
-55,289
-50% -$1.76M 1.4% 35
2014
Q4
$3.27M Sell
110,551
-1,101
-1% -$31.6K 2.36% 10
2014
Q3
$3.13M Hold
111,652
2.43% 10
2014
Q2
$3.14M Sell
111,652
-2,003
-2% -$57.1K 2.41% 11
2014
Q1
$3.46M Sell
113,655
-2,224
-2% -$66.3K 2.81% 5
2013
Q4
$3.37M Sell
115,879
-9,775
-8% -$284K 2.75% 8
2013
Q3
$3.42M Sell
125,654
-2,956
-2% -$80.4K 3.06% 4
2013
Q2
$3.42M Buy
+128,610
New +$3.55M 3.16% 4

Other funds holding PFE

Murphy Pohlad Asset Management's PFE Position: Q2 2026 in Review

Murphy Pohlad Asset Management reduced its Pfizer (PFE) stake by 9.6% in Q2 2026, selling an estimated $145K and leaving 52,377 shares worth $1.26M. The position accounts for 0.44% of the portfolio, ranked #69.

Murphy Pohlad Asset Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.09M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Murphy Pohlad Asset Management held 52,377 shares of Pfizer worth $1.26M as of Q2 2026.
  • Murphy Pohlad Asset Management sold 5,560 Pfizer shares in Q2 2026, an estimated $145K.
  • Pfizer made up 0.44% of Murphy Pohlad Asset Management's portfolio in Q2 2026, its #69 holding.
  • Murphy Pohlad Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Murphy Pohlad Asset Management's Pfizer position peaked at $6.09M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Murphy Pohlad Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.